查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1772195

癌症基因治疗市场规模、份额、趋势分析报告：按适应症、载体类型、给药途径、地区和细分市场预测，2025-2030 年

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Indication, By Vector Type, By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

癌症基因治疗市场的成长与趋势：

根据Grand View Research的最新报告，到2030年全球癌症基因治疗市场规模预计将达到127.6亿美元。

由于全球对新型治疗药物的需求不断增长以及全球癌症发病率的上升，预计该市场在2025年至2030年间的复合年增长率将达到19.34%。此外，该治疗方法为各种遗传性和诱发性癌症提供了绝对的解决方案，使其成为更理想的癌症治疗选择。例如，Kite公司的Tecartus（brexucabtagene autoleucel）已获得FDA核准，用于治疗復发或难治性B细胞前驱急性淋巴细胞白血病。

全球恶性肿瘤的发生率不断上升，预计这将推动对有效治疗方案和各种策略的需求，以应对恶性肿瘤日益增长的发病率。此外，市场技术进步预计将为新型疗法带来新的机会。因此，核准的产品数量正在增加。例如，2022年3月，欧洲药品管理局建议有条件地核准Carvykti（ciltacabtagene autoleucel）用于治疗復发和难治性多发性骨髓瘤。

世界各国政府和国家癌症协会的大力支持正积极推动市场发展。人们越来越重视增加癌症基因治疗的研究经费。例如，2021年12月，一个名为DARE-NL（荷兰）的荷兰平台获得了KWF荷兰癌症协会520万美元的津贴。这笔津贴将使DARE-NL能够提升细胞和基因治疗策略，使弱势族群能够获得更便利的治疗方案。

亚洲製造商对新型复杂技术的投资较少，因为他们专注于可以大量生产的简单分子，而欧洲和北美等其他已开发地区的製造商则投资高产量、低成本的技术，以避免竞争压力。

市场上的主要参与者正致力于合作开发强效的癌症基因治疗药物。例如，2022年8月，Gensaic与Ovid Therapeutics签署了一项合作协议，利用该公司专有的噬菌体衍生颗粒基因治疗平台，开发最多三种用于中枢神经系统疾病的基因药物。

癌症基因治疗市场报告重点

  • 随着我们对基因层面癌症病理学的理解不断进步，以及对基因导向免疫疗法和个人化医疗的需求不断增加，市场正在发生重大变化。
  • 由于基因诱导免疫治疗研究的进展，基因诱导免疫治疗领域将在2024年占据最大份额。
  • 对新型基因疗法的需求不断增长以及 FDA 对癌症基因疗法核准数量的不断增加，使得生物製药公司在 2024 年占据了最大的市场占有率。由于该领域研发活动的增加，预计生物製药公司在预测期内将呈现最快的成长速度。
  • 由于主要企业的存在以及政府和国家癌症研究所为促进该地区癌症研究而加强的支持力度，北美在 2024 年占据了市场主导地位。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影响分析

第四章癌症基因治疗市场：适应症业务分析

  • 指示细分仪表板
  • 全球癌症基因治疗市场趋势及波动分析
  • 全球癌症基因治疗市场规模及趋势分析（依适应症，2018-2030）
  • 大B细胞淋巴瘤
  • 多发性骨髓瘤
  • 急性淋巴性白血病（ALL）
  • 黑色素瘤（病变）
  • 其他的

第五章癌症基因治疗市场：给药途径业务分析

  • 给药途径细分仪表板
  • 全球癌症基因治疗市场给药途径变化分析
  • 全球癌症基因治疗市场规模及趋势分析（依给药途径，2018-2030）
  • 静脉
  • 其他的

第六章癌症基因治疗市场：载体类型的商业分析

  • 向量类型细分仪表板
  • 全球癌症基因治疗市场中基于载体的变异分析
  • 全球癌症基因治疗市场规模及趋势分析（依载体类型，2018-2030年）
  • 慢病毒
  • 逆转录病毒和γ逆转录病毒
  • AAV
  • 改良单纯疱疹病毒
  • 腺病毒
  • 其他的

第七章 癌症基因治疗市场：依适应症、给药途径和载体类型进行的区域估计和趋势分析

  • 区域仪表板
  • 2018年至2030年市场规模、预测与趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 瑞士
  • 亚太地区
    • 日本
    • 中国
    • 韩国
  • 世界其他地区

第八章 竞争态势

  • 参与企业
  • 战略地图
  • 2024年企业市场分析
  • 参与企业概况
    • Amgen Inc.
    • Novartis AG
    • Gilead Sciences, Inc.
    • bluebird bio, Inc.
    • Bristol-Myers Squibb Company
    • Legend Biotech.
    • Nanjing IASO Biotechnology
    • JW Therapeutics
    • CARsgen Therapeutics
    • Krystal Biotech, Inc.
Product Code: GVR-4-68039-984-2

Cancer Gene Therapy Market Growth & Trends:

The global cancer gene therapy market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.34% from 2025 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

  • The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine.
  • The gene induced immunotherapy segment held the largest share in 2024 due to increase in the advancement in gene induced immunotherapy research.
  • Biopharmaceutical companies held the largest market share in 2024 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field.
  • North America dominated the market in 2024 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Indication
    • 1.2.2. Route of Administration
    • 1.2.3. Vector Type
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Advancements in gene therapy technology
      • 3.2.1.3. Increasing adopton of personalized medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High costs of treatment
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gene Therapy Market: Indication Business Analysis

  • 4.1. Indication Segment Dashboard
  • 4.2. Global Cancer Gene Therapy Market Indication, Movement Analysis
  • 4.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Large B-Cell Lymphoma
    • 4.4.1. Global Large B-Cell Lymphoma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Multiple Myeloma
    • 4.5.1. Global Multiple Myeloma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Acute Lymphoblastic Leukemia (ALL)
    • 4.6.1. Global Acute Lymphoblastic Leukemia (ALL) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Melanoma (lesions)
    • 4.7.1. Global Melanoma (lesions) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Segment Dashboard
  • 5.2. Global Cancer Gene Therapy Market Route of Administration Movement Analysis
  • 5.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Intravenous
    • 5.4.1. Global Intravenous Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: VectorType Business Analysis

  • 6.1. Vector Type Segment Dashboard
  • 6.2. Global Cancer Gene Therapy Market Vector Type Movement Analysis
  • 6.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Vector Type, 2018 to 2030 (USD Million)
  • 6.4. Lentivirus
    • 6.4.1. Global Lentivirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. RetroVirus & gamma RetroVirus
    • 6.5.1. Global RetroVirus & gamma RetroVirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. AAV
    • 6.6.1. Global AAV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Modified Herpes Simplex Virus
    • 6.7.1. Global Modified Herpes Simplex Virus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Adenovirus
    • 6.8.1. Global Adenovirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Indication, Route of Administration, & Vector Type

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Switzerland
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. South Korea
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. South Korea Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Rest of the World
    • 7.6.1. Rest of the World Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Participant's Overview
    • 8.4.1. Amgen Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Gilead Sciences, Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. bluebird bio, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Bristol-Myers Squibb Company
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Legend Biotech.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Nanjing IASO Biotechnology
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. JW Therapeutics
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. CARsgen Therapeutics
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Krystal Biotech, Inc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 4 Global cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 6 Global cancer gene therapy market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 9 North America cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 11 U.S. cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 12 U.S. cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 13 U.S. cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 14 Canada cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Canada cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 Canada cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 17 Mexico cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 18 Mexico cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 20 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 22 Europe cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 24 UK cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 25 UK cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 UK cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 27 Germany cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Germany cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29 Germany cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 30 Switzerland cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Switzerland cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Switzerland cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 37 Japan cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Japan cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 40 China cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 41 China cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 42 China cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 43 South Korea cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 44 South Korea cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45 South Korea cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 46 Rest of the world cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Rest of the world cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Rest of the world cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 49 Participant's overview
  • Table 50 Financial performance
  • Table 51 Key companies undergoing expansions
  • Table 52 Key companies undergoing acquisitions
  • Table 53 Key companies undergoing collaborations
  • Table 54 Key companies launching new products
  • Table 55 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Cancer gene therapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Cancer gene therapy market driver analysis
  • Fig. 12 Cancer gene therapy market restraint analysis
  • Fig. 13 Cancer gene therapy market: Porter's analysis
  • Fig. 14 Cancer gene therapy market: PESTEL analysis
  • Fig. 15 Cancer gene therapy market: Indication outlook and key takeaways
  • Fig. 16 Cancer gene therapy market: Indication market share analysis, 2024 - 2030
  • Fig. 17 Global cancer gene therapy by large B-cell lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 18 Global cancer gene therapy by multiple myeloma market, 2018 - 2030 (USD Million)
  • Fig. 19 Global cancer gene therapy by Acute Lymphoblastic Leukemia (ALL) market, 2018 - 2030 (USD Million)
  • Fig. 20 Global cancer gene therapy by melanoma (lesions) market, 2018 - 2030 (USD Million)
  • Fig. 21 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 22 Cancer gene therapy market: Route of administration outlook and key takeaways
  • Fig. 23 Cancer gene therapy market: Route of administration market share analysis, 2024 - 2030
  • Fig. 24 Global cancer gene therapy by intravenous market, 2018 - 2030 (USD Million)
  • Fig. 25 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 26 Cancer gene therapy market: Vector type outlook and key takeaways
  • Fig. 27 Cancer gene therapy market: Vector type market share analysis, 2024 - 2030
  • Fig. 28 Global cancer gene therapy by lentivirus market, 2018 - 2030 (USD Million)
  • Fig. 29 Global cancer gene therapy by retrovirus & gamma retrovirus market, 2018 - 2030 (USD Million)
  • Fig. 30 Global cancer gene therapy by AAV market, 2018 - 2030 (USD Million)
  • Fig. 31 Global cancer gene therapy by modified herpes simplex virus market, 2018 - 2030 (USD Million)
  • Fig. 32 Global cancer gene therapy by adenovirus market, 2018 - 2030 (USD Million)
  • Fig. 33 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Canada cancer gene therapy market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Europe cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 UK cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Germany cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Switzerland cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Asia-Pacific cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Japan cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 China cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Rest of the world cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key company categorization
  • Fig. 49 Company market positioning
  • Fig. 50 Market participant categorization
  • Fig. 51 Strategy framework